Skip to entry

Semaglutide doses and indications, as labeled

GLP1Meds.org editorial team · Published November 18, 2026 · Last reviewed November 18, 2026

Semaglutide is one molecule sold under more than one label. The milligrams on a Wegovy pen, a Wegovy tablet, an Ozempic pen, and a Rybelsus tablet are not a single ladder you can climb by adding the numbers. This entry restates the schedules and the trial result most often quoted for weight reduction. It is not an order to take any of those doses. Cash prices for the Wegovy presentations are tabulated, with dates, on the cash-price sheet. How the common gastrointestinal effects were counted is discussed for patients in a side-effects note.

Wegovy injection

The DailyMed label reviewed on November 18, 2026, describes Wegovy injection as a GLP-1 receptor agonist given subcutaneously once weekly in the abdomen, thigh, or upper arm, on the same day each week, with or without meals. Escalation for adults and for pediatric patients 12 and older uses one table.

Weeks Weekly dose
1 through 4 0.25 mg
5 through 8 0.5 mg
9 through 12 1 mg
13 through 16 1.7 mg
17 onward Maintenance, by indication

For adult weight reduction, maintenance is 1.7 mg or 2.4 mg, and 2.4 mg is the recommended maintenance. If 2.4 mg is tolerated for at least four weeks and additional weight reduction is clinically indicated, the dose may be increased to a maximum of 7.2 mg weekly. The label tells prescribers to consider response and tolerability. For cardiovascular risk reduction in adults, maintenance is 2.4 mg (recommended) or 1.7 mg. For weight reduction in adolescents 12 and older, maintenance is 2.4 mg (recommended) or 1.7 mg. For noncirrhotic MASH with moderate to advanced fibrosis, the recommended maintenance is 2.4 mg, with a decrease to 1.7 mg if 2.4 mg is not tolerated and a possible return to 2.4 mg. If a step during escalation is not tolerated, the label says to consider delaying escalation for four weeks.

A missed injection: if the next scheduled dose is more than two days away, give the missed dose as soon as possible. If the next dose is less than two days away, skip the missed dose. If two or more consecutive doses are missed, reinitiate escalation at a lower dose to reduce gastrointestinal adverse reactions.

Switching between the 2.4 mg injection and the 25 mg tablet is described on the label and is not a home calculation. Patients on 2.4 mg injection may switch to 25 mg tablets, starting the tablet one week after the last injection. The reverse switch starts 2.4 mg injection the day after the last 25 mg tablet. People who do not tolerate 25 mg tablets may be considered for 1.7 mg injection. Do not run both at once. Concomitant use with any other semaglutide product or GLP-1 receptor agonist is not recommended.

STEP 1 randomized 1,961 adults with BMI of at least 30, or at least 27 with a weight-related condition, and without diabetes, to semaglutide 2.4 mg or placebo plus lifestyle intervention for 68 weeks. Mean weight change was −14.9 percent versus −2.4 percent, a difference of −12.4 percentage points. At least 5 percent loss occurred in 86.4 percent versus 31.5 percent. Nausea and diarrhea were the most common adverse events. Gastrointestinal events led to discontinuation in 4.5 percent versus 0.8 percent. The label’s pooled safety tables, which include this program, report nausea in 44 percent versus 16 percent, vomiting in 25 percent versus 6 percent, and diarrhea in 30 percent versus 16 percent among adults in the weight-reduction trials of the 2.4 mg injection. STEP 4 later showed that people who continued semaglutide after a 20-week run-in kept losing weight, while people switched to placebo regained, on average. That trial is summarized in the maintenance literature. It is not a reason to start at 2.4 mg.

Storage depends on the device. Single-dose pens and syringes are refrigerated at 36°F to 46°F, protected from light in the carton, not frozen, and may be kept at 46°F to 86°F for up to 28 days before the cap is removed. The label describes a different in-use window for the FlexTouch single-patient-use pen. Tablets are stored at controlled room temperature in the original bottle, protected from moisture. Read the carton that matches the device you were dispensed.

Wegovy tablets

Tablets are taken once daily in the morning on an empty stomach with up to 4 ounces of water only. Swallow them whole. Wait at least 30 minutes before food, other drinks, or other oral medicines. Do not take more than one tablet a day. A missed tablet is skipped.

Days Daily dose
1 through 30 1.5 mg
31 through 60 4 mg
61 through 90 9 mg
91 onward 25 mg

The recommended maintenance for the adult cardiovascular and weight-reduction uses is 25 mg daily. If 25 mg is not tolerated, the label says to consider switching to Wegovy injection 1.7 mg weekly. If a dose during escalation is not tolerated, delaying escalation is an option. These strengths are not Rybelsus strengths. They are not added together to imitate an injection.

Ozempic injection and the diabetes tablets

Ozempic injection starts at 0.25 mg weekly for four weeks, then 0.5 mg. If more glycemic control is needed, the dose may increase to 1 mg after at least four weeks on 0.5 mg, and to 2 mg after at least four weeks on 1 mg. For the kidney-risk indication, the label says to increase to 1 mg weekly after at least four weeks on 0.5 mg. A missed dose is given as soon as possible within five days, which is a different window from Wegovy’s two-day rule. The injection is subcutaneous in the abdomen, thigh, or upper arm.

Rybelsus, on the DailyMed record reviewed, starts at 3 mg orally once daily for 30 days. The label says that dose is not effective for glycemic control. The dose then increases to 7 mg daily. On day 61 or after, it stays at 7 mg if no more control is needed, or increases to 14 mg if it is. Administration is the empty-stomach, small-water, 30-minute-wait pattern. A missed dose is skipped. The same record states that Rybelsus and Ozempic tablets are not substitutable milligram for milligram. This entry does not invent an Ozempic-tablet titration beyond that warning. Open the dosing subsection of that label before anyone converts a pen dose into a tablet dose.

Contraindications and the warnings prescribers counsel

Wegovy is contraindicated with a personal or family history of medullary thyroid carcinoma, with MEN 2, and with prior serious hypersensitivity to semaglutide or to an excipient in that presentation. The boxed warning states that semaglutide causes thyroid C-cell tumors in rodents and that human relevance is unknown. Patients are counseled on symptoms of thyroid tumors: a neck mass, dysphagia, dyspnea, persistent hoarseness. Routine calcitonin or ultrasound screening is of uncertain value, according to the label.

Pancreatitis, including fatal cases, has been observed. Severe abdominal pain, sometimes radiating to the back, with or without vomiting, is the symptom cluster that should stop the drug and prompt care. Gallbladder disease is increased relative to placebo in the figures cited above. Acute kidney injury has been reported after gastrointestinal fluid loss. Diabetic retinopathy complications were reported more often than placebo in a Wegovy trial of adults with type 2 diabetes and BMI at least 27. Hypoglycemia risk rises with insulin or a sulfonylurea. The label says Wegovy may cause fetal harm and, for weight reduction or cardiovascular risk reduction, should be stopped when pregnancy is recognized and at least two months before a planned pregnancy. Breastfeeding is not recommended during treatment with Wegovy tablets. Heart rate increased in the trials. Pulmonary aspiration during anesthesia or deep sedation is a warning to share with a surgical team.

The class map is in which GLP-1 medicines. Nothing in STEP 1 removes a contraindication. A 14.9 percent mean is not a personal forecast, and it was produced with lifestyle intervention in people without diabetes, at a dose reached only after months of escalation.

Label and trial list

  1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  2. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42bdd912-2393-44c4-b7e0-47672ca28991
  3. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
  4. https://pubmed.ncbi.nlm.nih.gov/33567185/
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC7988425/
  6. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215256
  7. https://glp1journey.org/notes/side-effects
  8. https://glp1rx.org/steps/cash-prices